T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice

European Journal of Haematology

Volumn 86, Issue 2, 2011, Pages 156-166

  Kumfu, Sirinart ^a   Chattipakorn, Siriporn ^a,b   Srichairatanakool, Somdet ^a   Settakorn, Jongkolnee ^a   Fucharoen, Suthat ^c   Chattipakorn, Nipon ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Cardiomyocytes; Iron overload; L type calcium channel; T type calcium channel; Thalassemia

Indexed keywords

ASCORBIC ACID; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CD71 ANTIGEN; COMPLEMENTARY RNA; DEFEROXAMINE; EBSELEN; EFONIDIPINE; IRON; MESSENGER RNA; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; RNA; TRANSFERRIN RECEPTOR 2; VERAPAMIL; ZINC TRANSPORTER;

ANIMAL CELL; ARTICLE; BETA THALASSEMIA; CARDIOMYOPATHY; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; GENE EXPRESSION; HEART MUSCLE CELL; IMMUNOCYTOCHEMISTRY; IRON OVERLOAD; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; BETA-THALASSEMIA; CALCIUM CHANNELS, T-TYPE; CELL SURVIVAL; CELLS, CULTURED; DEFEROXAMINE; DISEASE MODELS, ANIMAL; FLUORESCEINS; HETEROZYGOTE; IMMUNOHISTOCHEMISTRY; IRON; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; VERAPAMIL;

EID: 78651447796     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01549.x     Document Type: Article

References (38)

1. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-95.
2. Weatherall DJ, Clegg JB. Thalassemia - a global public health problem. Nat Med 1996;2:847-9.
3. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004;117:285-97.
4. Breuer W, Shvartsman M, Cabantchik ZI. Intracellular labile iron. Int J Biochem Cell Biol 2008;40:350-4.
5. Lekawanvijit S, Chattipakorn N. Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. Can J Cardiol 2009;25:213-8.
6. Wood JC, Enriquez C, Ghugre N, Otto-Duessel M, Aguilar M, Nelson MD, Moats R, Coates TD. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci 2005;1054:386-95.
7. Rutjanaprom W, Kanlop N, Charoenkwan P, Sittiwangkul R, Srichairatanakool S, Tantiworawit A, Phrommintikul A, Chattipakorn S, Fucharoen S, Chattipakorn N. Heart rate variability in beta-thalassemia patients. Eur J Haematol 2009;83:483-9.
8. Liu Y, Parkes JG, Templeton DM. Differential accumulation of non-transferrin-bound iron by cardiac myocytes and fibroblasts. J Mol Cell Cardiol 2003;35:505-14.
9. Ke Y, Chen YY, Chang YZ, Duan XL, Ho KP, Jiang DH, Wang K, Qian ZM. Post-transcriptional expression of DMT1 in the heart of rat. J Cell Physiol 2003;196:124-30.
10. Rodriguez A, Hilvo M, Kytomaki L, Fleming RE, Britton RS, Bacon BR, Parkkila S. Effects of iron loading on muscle: genome-wide mRNA expression profiling in the mouse. BMC Genomics 2007;8:379.
11. Parkes JG, Liu Y, Sirna JB, Templeton DM. Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts. J Mol Cell Cardiol 2000;32:233-46.
12. Tsushima RG, Wickenden AD, Bouchard RA, Oudit GY, Liu PP, Backx PH. Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload. Circ Res 1999;84:1302-9.
13. Oudit GY, Sun H, Trivieri MG, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003;9:1187-94.
14. Parkes JG, Olivieri NF, Templeton DM. Characterization of Fe2+ and Fe3+ transport by iron-loaded cardiac myocytes. Toxicology 1997;117:141-51.
15. Niwa N, Yasui K, Opthof T, Takemura H, Shimizu A, Horiba M, Lee JK, Honjo H, Kamiya K, Kodama I. Cav3.2 subunit underlies the functional T-type Ca2+ channel in murine hearts during the embryonic period. Am J Physiol Heart Circ Physiol 2004;286:H2257-63.
16. Yasui K, Niwa N, Takemura H, et al. Pathophysiological significance of T-type Ca2+ channels: expression of T-type Ca2+ channels in fetal and diseased heart. J Pharmacol Sci 2005;99:205-10.
17. Martinez ML, Heredia MP, Delgado C. Expression of T-type Ca(2+) channels in ventricular cells from hypertrophied rat hearts. J Mol Cell Cardiol 1999;31:1617-25.
18. Huang B, Qin D, Deng L, Boutjdir M, N E-S. Reexpression of T-type Ca2+ channel gene and current in post-infarction remodeled rat left ventricle. Cardiovasc Res 2000;46:442-9.
19. Jamsai D, Zaibak F, Khongnium W, Vadolas J, Voullaire L, Fowler KJ, Gazeas S, Fucharoen S, Williamson R, Ioannou PA. A humanized mouse model for a common beta0-thalassemia mutation. Genomics 2005;85:453-61.
20. Jamsai D, Zaibak F, Vadolas J, Voullaire L, Fowler KJ, Gazeas S, Peters H, Fucharoen S, Williamson R, Ioannou PA. A humanized BAC transgenic/knockout mouse model for HbE/beta-thalassemia. Genomics 2006;88:309-15.
21. Incharoen T, Thephinlap C, Srichairatanakool S, Chattipakorn S, Winichagoon P, Fucharoen S, Vadolas J, Chattipakorn N. Heart rate variability in beta-thalassemic mice. Int J Cardiol 2007;121:203-4.
22. Song W, Lu X, Feng Q. Tumor necrosis factor-alpha induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes. Cardiovasc Res 2000;45:595-602.
23. Dyntar D, Eppenberger-Eberhardt M, Maedler K, Pruschy M, Eppenberger HM, Spinas GA, Donath MY. Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 2001;50:2105-13.
24. Dyntar D, Sergeev P, Klisic J, Ambuhl P, Schaub MC, Donath MY. High glucose alters cardiomyocyte contacts and inhibits myofibrillar formation. J Clin Endocrinol Metab 2006;91:1961-7.
25. Eppenberger HM, Zuppinger C. In vitro reestablishment of cell-cell contacts in adult rat cardiomyocytes. Functional role of transmembrane components in the formation of new intercalated disk-like cell contacts. FASEB J 1999;13(Suppl):S83-9.
26. Li Z, Gu TX, Zhang YH. Hepatocyte growth factor combined with insulin like growth factor-1 improves expression of GATA-4 in mesenchymal stem cells cocultured with cardiomyocytes. Chin Med J (Engl) 2008;121:336-40.
27. Fukuda K. Use of adult marrow mesenchymal stem cells for regeneration of cardiomyocytes. Bone Marrow Transplant 2003;32(Suppl 1):S25-7.
28. Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006;108:3195-203.
29. Shvartsman M, Kikkeri R, Shanzer A, Cabantchik ZI. Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications. Am J Physiol Cell Physiol 2007;293:C1383-94.
30. Vassort G, Talavera K, Alvarez JL. Role of T-type Ca2+ channels in the heart. Cell Calcium 2006;40:205-20.
31. Wetli HA, Buckett PD, Wessling-Resnick M. Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake. Chem Biol 2006;13:965-72.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
33. Kitagawa-Sakakida S, Fukushima N, Sawa Y, Horiguchi K, Doi T, Shirakura R, Matsuda H. Microarray-based gene expression profiling of retransplanted rat cardiac allografts that develop cardiac allograft vasculopathy. J Heart Lung Transplant 2005;24:2068-74.
34. Davis MT, Bartfay WJ. Ebselen decreases oxygen free radical production and iron concentrations in the hearts of chronically iron-overloaded mice. Biol Res Nurs 2004;6:37-45.
35. Yang B, Kirby S, Lewis J, Detloff PJ, Maeda N, Smithies O. A mouse model for beta 0-thalassemia. Proc Natl Acad Sci U S A 1995;92:11608-12.
36. Thephinlap C, Phisalaphong C, Fucharoen S, Porter JB, Srichairatanakool S. Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice. Med Chem 2009;5:474-82.
37. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.
38. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.